Exhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosis
- PMID: 27730156
- PMCID: PMC5005121
- DOI: 10.1183/23120541.00044-2015
Exhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosis
Abstract
Hydrogen cyanide is readily detected in the headspace above Pseudomonas aeruginosa cultures and in the breath of cystic fibrosis (CF) patients with chronic (P. aeruginosa) infection. We investigated if exhaled breath HCN is an early marker of P. aeruginosa infection. 233 children with CF who were free from P. aeruginosa infection were followed for 2 years. Their median (interquartile range) age was 8.0 (5.0-12.2) years. At each study visit, an exhaled breath sample was collected for hydrogen cyanide analysis. In total, 2055 breath samples were analysed. At the end of the study, the hydrogen cyanide concentrations were compared to the results of routine microbiology surveillance. P. aeruginosa was isolated from 71 children during the study with an incidence (95% CI) of 0.19 (0.15-0.23) cases per patient-year. Using a random-effects logistic model, the estimated odds ratio (95% CI) was 3.1 (2.6-3.6), which showed that for a 1- ppbv increase in exhaled breath hydrogen cyanide, we expected a 212% increase in the odds of P. aeruginosa infection. The sensitivity and specificity were estimated at 33% and 99%, respectively. Exhaled breath hydrogen cyanide is a specific biomarker of new P. aeruginosa infection in children with CF. Its low sensitivity means that at present, hydrogen cyanide cannot be used as a screening test for this infection.
Conflict of interest statement
Conflicts of Interest: None declared.
Figures
Similar articles
-
Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without Pseudomonas aeruginosa infection.J Breath Res. 2013 Jun;7(2):026010. doi: 10.1088/1752-7155/7/2/026010. Epub 2013 May 17. J Breath Res. 2013. PMID: 23680696
-
Hydrogen cyanide as a biomarker for Pseudomonas aeruginosa in the breath of children with cystic fibrosis.Pediatr Pulmonol. 2009 Feb;44(2):142-7. doi: 10.1002/ppul.20963. Pediatr Pulmonol. 2009. PMID: 19148935
-
Hydrogen cyanide, a volatile biomarker of Pseudomonas aeruginosa infection.J Breath Res. 2013 Dec;7(4):044001. doi: 10.1088/1752-7155/7/4/044001. Epub 2013 Nov 28. J Breath Res. 2013. PMID: 24287489 Review.
-
Quantification of hydrogen cyanide (HCN) in breath using selected ion flow tube mass spectrometry--HCN is not a biomarker of Pseudomonas in chronic suppurative lung disease.J Breath Res. 2013 Mar;7(1):017105. doi: 10.1088/1752-7155/7/1/017105. Epub 2013 Feb 27. J Breath Res. 2013. PMID: 23445778
-
Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients.J Cyst Fibros. 2022 Jan;21(1):e28-e34. doi: 10.1016/j.jcf.2021.04.015. Epub 2021 May 18. J Cyst Fibros. 2022. PMID: 34016557 Review.
Cited by
-
Volatilomes of human infection.Anal Bioanal Chem. 2024 Jan;416(1):37-53. doi: 10.1007/s00216-023-04986-z. Epub 2023 Oct 16. Anal Bioanal Chem. 2024. PMID: 37843549 Free PMC article. Review.
-
Quantification of volatile metabolites in exhaled breath by selected ion flow tube mass spectrometry, SIFT-MS.Clin Mass Spectrom. 2020 Feb 13;16:18-24. doi: 10.1016/j.clinms.2020.02.001. eCollection 2020 Apr. Clin Mass Spectrom. 2020. PMID: 34820516 Free PMC article. Review.
-
Cysteamine Inhibits Glycine Utilisation and Disrupts Virulence in Pseudomonas aeruginosa.Front Cell Infect Microbiol. 2021 Sep 22;11:718213. doi: 10.3389/fcimb.2021.718213. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34631600 Free PMC article.
-
The two faces of cyanide: an environmental toxin and a potential novel mammalian gasotransmitter.FEBS J. 2022 May;289(9):2481-2515. doi: 10.1111/febs.16135. Epub 2021 Aug 5. FEBS J. 2022. PMID: 34297873 Free PMC article. Review.
-
Biomarkers in Cystic Fibrosis Lung Disease - A Review.Rom J Anaesth Intensive Care. 2020 Dec;27(2):34-36. doi: 10.2478/rjaic-2020-0011. Epub 2020 Oct 11. Rom J Anaesth Intensive Care. 2020. PMID: 34056131 Free PMC article. Review.
References
-
- Emerson J, Rosenfeld M, McNamara S, et al. . Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91–100. - PubMed
-
- Nixon GM, Armstrong DS, Carzino R, et al. . Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 138: 699–704. - PubMed
-
- Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338: 725–726. - PubMed
-
- Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009: CD004197. - PubMed
-
- Douglas TA, Brennan S, Gard S, et al. . Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009; 33: 305–311. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources